Blocknomi
Key Takeaways Shares of Amylyx rose approximately 21% during pre-market hours following positive Phase 3 data showing avexitide, a GLP-1 receptor antagonist, achieved all primary and secondary study goals Participants…
Related articles
-
Jim Cramer plans to sell his Bitcoin over quantum fears as BTC rises 1.6%
Cointelegraph Published 04.08.2026 10:47
-
Crypto Wrench Attacks on Pace for Record Year as $30M Stolen in 2026: Chainalysis
Decrypt Published 06.08.2026 12:01
-
USDC redemptions just outpaced mints by $4B, but a massive new token presale is quietly doubling Circle’s revenue outlook
CryptoSlate Published 05.08.2026 18:20
-
Senate delays Clarity Act vote until after August recess, Thune confirms
The Block Published 07.08.2026 02:55
-
Shytoshi Kusama's Litecoin Connection? SHIB Veteran Gives Take
U.Today Published 14.08.2026 10:30
-
Individuals still hold the most Bitcoin
Crypto.News Published 04.08.2026 12:36
-
Swiss Banking Giant UBS Doubles Down on Bitcoin ETF Exposure
Bitcoin.com Published 13.08.2026 18:53
-
ZoomInfo (GTM) Stock: Company Launches MCP Connector for Microsoft Copilot Studio
Blocknomi Published 11.08.2026 19:00